New Delhi, Jul 18 (PTI) Dr Reddy's Laboratories on Thursday said it has inked a licensing pact with Takeda Pharmaceutical Company to commercialise Vonoprazan tablets in India.

Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders.

Also Read | Shillong Teer Results Today, July 18 2024: Winning Numbers, Result Chart for Shillong Morning Teer, Shillong Night Teer, Khanapara Teer, Juwai Teer and Jowai Ladrymbai.

The company has entered into a non-exclusive patent licensing agreement with Takeda for the commercialisation of the product, the Hyderabad-based drug firm said in a statement.

Dr Reddy's said it will market Vonoprazan tablets under its own trademark Vono in strength of 10mg and 20mg, it added.

Also Read | Ladla Bhai Yojana in Maharashtra: From Eligibility Criteria to Benefits and How To Apply, Here's All You Need To Know.

"The non-exclusive patent licensing agreement with Takeda is part of our continuous efforts to make innovative medicines available to patients in India through strategic collaborations to meet unmet needs and enhance standard of care," Dr Reddy's CEO - Branded Markets (India & Emerging Markets) MV Ramana stated.

Shares of Dr Reddy's ended 0.33 per cent higher at Rs 6,665.10 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)